{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:12Z","timestamp":1793192472513,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microvascular Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.mvr.2026.104955","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:38:34Z","timestamp":1776728314000},"page":"104955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Microvascular and stromal normalization combined with nano-immunotherapy: A synergistic strategy to overcome drug delivery barriers in solid tumors"],"prefix":"10.1016","volume":"166","author":[{"given":"Fatemeh","family":"Mirala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad Moradi","family":"Kashkooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mvr.2026.104955_bb0005","series-title":"Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy","first-page":"229","article-title":"Imaging the tumor microenvironment","author":"Abadjian","year":"2017"},{"issue":"8","key":"10.1016\/j.mvr.2026.104955_bb0010","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-23-2823","article-title":"Clinical activity of TGF-\u03b2 inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib\/II study","volume":"30","author":"Ahn","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mvr.2026.104955_bb0015","series-title":"Cold Spring Harbor Symposia on Quantitative Biology","article-title":"Trimming the vascular tree in tumors: metabolic and immune adaptations","author":"Allen","year":"2016"},{"issue":"16","key":"10.1016\/j.mvr.2026.104955_bb0020","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"issue":"6","key":"10.1016\/j.mvr.2026.104955_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.mvr.2026.104955_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med."},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0035","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric Nanoparticles for Drug Delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00253-024-13211-5","article-title":"Mechanical models and measurement methods of solid stress in tumors","volume":"108","author":"Bi","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.mvr.2026.104955_bb0050","article-title":"The future of liquid biopsy","volume":"12","author":"Biswas","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0055","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0060","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/path.5914","article-title":"Leveraging single-cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers","volume":"257","author":"Bowes","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.mvr.2026.104955_bb0065","series-title":"Pericytes Orchestrate a Tumor-restraining Microenvironment in Glioblastoma","author":"Braun","year":"2024"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0070","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","article-title":"Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas","volume":"15","author":"Broz","year":"2024","journal-title":"Nat. Commun."},{"issue":"7347","key":"10.1016\/j.mvr.2026.104955_bb0075","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.mvr.2026.104955_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0085","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201802070","article-title":"Therapeutic remodeling of the tumor microenvironment enhances nanoparticle delivery","volume":"6","author":"Chen","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mvr.2026.104955_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1093240","article-title":"Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy","volume":"12","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.mvr.2026.104955_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202063","article-title":"Smart nanoparticle-based platforms for regulating tumor microenvironment and cancer immunotherapy","volume":"12","author":"Cheng","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/cancers3010213","article-title":"Vitamin D and pancreatic cancer\u2014an update","volume":"3","author":"Chiang","year":"2011","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.mvr.2026.104955_bb0115","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.mvr.2026.104955_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16183211","article-title":"Vitamin D in cancer prevention and treatment: a review of epidemiological, preclinical, and cellular studies","volume":"16","author":"Dallavalasa","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.mvr.2026.104955_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.mvr.2026.104955_bb0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0150","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1152\/physrev.00053.2021","article-title":"Vascular mechanotransduction","volume":"103","author":"Davis","year":"2023","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.mvr.2026.104955_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118814","article-title":"Dendrimers in the context of nanomedicine","volume":"573","author":"Dias","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"64","key":"10.1016\/j.mvr.2026.104955_bb0160","doi-asserted-by":"crossref","first-page":"17148","DOI":"10.1002\/chem.201804153","article-title":"Folic acid functionalized zirconium-based metal-organic frameworks as drug carriers for active tumor-targeted drug delivery","volume":"24","author":"Dong","year":"2018","journal-title":"Chemistry"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12392","article-title":"Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives","volume":"43","author":"Fang","year":"2023","journal-title":"Cancer Commun."},{"issue":"20","key":"10.1016\/j.mvr.2026.104955_bb0170","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050731","article-title":"Targeting HER2-positive solid tumors with CAR NK cells: CD44 expression is a critical modulator of HER2-specific CAR NK cell efficacy","volume":"17","author":"Gergely","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.mvr.2026.104955_bb0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-394311-8.00014-5","article-title":"Cadherins and epithelial-to-mesenchymal transition","volume":"116","author":"Gheldof","year":"2013","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.mvr.2026.104955_bb0190","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1097\/j.pain.0000000000003770","article-title":"Ozanimod, a functional sphingosine-1-phosphate receptor 1 antagonist, restores brainstem descending pain pathways in murine models of neuropathic pain","volume":"166","author":"Giancotti","year":"2025","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0195","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.mvr.2026.104955_bb0200","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.mvr.2026.104955_bb0205","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1080\/17425247.2020.1814735","article-title":"Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site","volume":"17","author":"Gouarderes","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mvr.2026.104955_bb0210","series-title":"Mathematical Modeling of the Tumor Microenvironment With the Aim of Studying Its Heterogeneity as a Driver of Treatment Resistance and a Potential Therapy Target","author":"Grajek","year":"2023"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.mvr.2026.104955_bb0225","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure\u2014an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mvr.2026.104955_bb0230","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.mvr.2026.104955_bb0235","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.mvr.2026.104955_bb0240","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","article-title":"Tumor microenvironment: Sanctuary of the devil","volume":"368","author":"Hui","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041232","article-title":"Resistance to anti-angiogenic therapy in cancer\u2014alterations to anti-VEGF pathway","volume":"19","author":"Itatani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.mvr.2026.104955_bb0260","first-page":"3039","article-title":"Transport of molecules in the tumor interstitium: a review","volume":"47","author":"Jain","year":"1987","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.mvr.2026.104955_bb0265","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0270","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mvr.2026.104955_bb0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-bioeng-071813-105259","article-title":"The role of mechanical forces in tumor growth and therapy","volume":"16","author":"Jain","year":"2014","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"30","key":"10.1016\/j.mvr.2026.104955_bb0280","article-title":"Dual intratumoral redox\/enzyme-responsive NO-releasing nanomedicine for the specific, high-efficacy, and low-toxic cancer therapy","volume":"30","author":"Jia","year":"2018","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003960","article-title":"Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy","volume":"10","author":"Jiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2741\/3614","article-title":"TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect","volume":"15","author":"Joshi","year":"2010","journal-title":"Front. Biosci."},{"issue":"6230","key":"10.1016\/j.mvr.2026.104955_bb0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0300","doi-asserted-by":"crossref","DOI":"10.1063\/5.0183302","article-title":"Toward innovative approaches for exploring the mechanically regulated tumor-immune microenvironment","volume":"8","author":"Kalli","year":"2024","journal-title":"APL Bioeng."},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0305","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mvr.2026.104955_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.586176","article-title":"The tumor microenvironment: Recent advances and novel therapeutic approaches","volume":"8","author":"Korkaya","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0315","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0320","article-title":"Combination drug delivery approaches in metastatic breast cancer","volume":"2012","author":"Lee","year":"2012","journal-title":"J. Drug Deliv."},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0325","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"24","key":"10.1016\/j.mvr.2026.104955_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16244194","article-title":"Chemokine CXCL12 activates CXC receptor 4 metastasis signaling through the upregulation of a CXCL12\/CXCR4\/MDMX (MDM4) axis","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.mvr.2026.104955_bb0335","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0340","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.14377","article-title":"Macrophage targeting in cancer","volume":"1499","author":"Lopez-Yrigoyen","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"5322","key":"10.1016\/j.mvr.2026.104955_bb0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"issue":"7693","key":"10.1016\/j.mvr.2026.104955_bb0355","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mvr.2026.104955_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061879","article-title":"The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review","volume":"15","author":"Marino","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030332","article-title":"Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare","volume":"16","author":"Marques","year":"2024","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0370","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"12_Part_1","key":"10.1016\/j.mvr.2026.104955_bb0375","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0385","article-title":"Mechanical forces in tumor growth and treatment: perspectives from biology, physics, engineering, and mathematical modeling","volume":"17","author":"Moradi Kashkooli","year":"2025","journal-title":"WIREs Mech. Dis."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mvr.2026.104955_bb0395","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s10237-015-0682-0","article-title":"Stress-mediated progression of solid tumors: effect of mechanical stress on tissue oxygenation, cancer cell proliferation, and drug delivery","volume":"14","author":"Mpekris","year":"2015","journal-title":"Biomech. Model. Mechanobiol."},{"issue":"7","key":"10.1016\/j.mvr.2026.104955_bb0400","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mvr.2026.104955_bb0405","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2022.03.008","article-title":"Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy","volume":"345","author":"Mpekris","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","article-title":"The mechanisms of nanoparticle delivery to solid tumours","volume":"2","author":"Nguyen","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"6516","key":"10.1016\/j.mvr.2026.104955_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz0868","article-title":"Physical traits of cancer","volume":"370","author":"Nia","year":"2020","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.mvr.2026.104955_bb0420","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.3390\/ijms23137091","article-title":"Effect of compressive stress in tumor microenvironment on malignant tumor spheroid invasion process","volume":"23","author":"Nishi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.mvr.2026.104955_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051318","article-title":"Drug delivery strategies for the treatment of pancreatic cancer","volume":"15","author":"Olajubutu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.mvr.2026.104955_bb0430","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1088\/0022-3727\/36\/13\/201","article-title":"Applications of magnetic nanoparticles in biomedicine","volume":"36","author":"Pankhurst","year":"2003","journal-title":"J. Phys. D. Appl. Phys."},{"key":"10.1016\/j.mvr.2026.104955_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112938","article-title":"The emerging promise of tumour mechanobiology in cancer treatment","volume":"190","author":"Papavassiliou","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.mvr.2026.104955_bb0440","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients with NSCLC: Results from an expansion cohort of a phase 1 trial","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.mvr.2026.104955_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071654","article-title":"Using quantitative imaging for personalized medicine in pancreatic cancer: a review of radiomics and deep learning applications","volume":"14","author":"Preuss","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.mvr.2026.104955_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune\u2013vascular crosstalk in cancer immunotherapy","volume":"14","author":"Qian","year":"2023","journal-title":"Front. Immunol."},{"issue":"46","key":"10.1016\/j.mvr.2026.104955_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202402308","article-title":"Zinc coordination lipid nanoparticles co-delivering calcium peroxide and chelating STING agonist for enhanced cancer metalloimmunotherapy","volume":"20","author":"Qiu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.mvr.2026.104955_bb0465","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2019.03.015","article-title":"Threatening cancer with nanoparticle aided combination oncotherapy","volume":"301","author":"Rawal","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0470","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.mvr.2026.104955_bb0475","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0480","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040840","article-title":"Targeting tumor microenvironment for cancer therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0490","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0495","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0500","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0505","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1389450117666160527142544","article-title":"Smart drug-delivery systems for cancer nanotherapy","volume":"19","author":"Sanchez-Moreno","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"481","key":"10.1016\/j.mvr.2026.104955_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2127","article-title":"Driving CAR T cell translation forward","volume":"11","author":"Schultz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0515","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.mvr.2026.104955_bb0520","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1021\/nl102184c","article-title":"Nanotechnology in drug delivery and tissue engineering: from discovery to applications","volume":"10","author":"Shi","year":"2010","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0525","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0530","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.mvr.2026.104955_bb0535","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int. Immunol."},{"issue":"38","key":"10.1016\/j.mvr.2026.104955_bb0540","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.mvr.2026.104955_bb0545","doi-asserted-by":"crossref","first-page":"390","DOI":"10.20517\/cdr.2023.16","article-title":"Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system","volume":"6","author":"Sun","year":"2023","journal-title":"Cancer Drug Resist."},{"issue":"6","key":"10.1016\/j.mvr.2026.104955_bb0550","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/1061186X.2024.2349124","article-title":"pH-responsive self-assembled nanoparticles for tumor-targeted drug delivery","volume":"32","author":"Sun","year":"2024","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0555","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.mvr.2026.104955_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030724","article-title":"Therapeutic strategies to overcome fibrotic barriers to nanomedicine in the pancreatic tumor microenvironment","volume":"15","author":"Tanaka","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0565","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16106","article-title":"Pericyte-expressed Tie2 controls angiogenesis and vessel maturation","volume":"8","author":"Teichert","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.mvr.2026.104955_bb0570","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/74725","article-title":"Angiopoietin-1 protects the adult vasculature against plasma leakage","volume":"6","author":"Thurston","year":"2000","journal-title":"Nat. Med."},{"issue":"46","key":"10.1016\/j.mvr.2026.104955_bb0575","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1073\/pnas.1518808112","article-title":"Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients","volume":"112","author":"Tolaney","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.mvr.2026.104955_bb0580","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.3390\/cancers12123526","article-title":"Visfatin enhances breast cancer progression through CXCL1 induction in tumor-associated macrophages","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.mvr.2026.104955_bb0585","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1039\/D5BM00544B","article-title":"Multifunctional metal-organic frameworks and their heterojunction materials for cancer theranostics","volume":"13","author":"Wang","year":"2025","journal-title":"Biomater. Sci."},{"issue":"11","key":"10.1016\/j.mvr.2026.104955_bb0590","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.mvr.2026.104955_bb0595","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0600","article-title":"Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors","volume":"2014","author":"Wong","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.mvr.2026.104955_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14101990","article-title":"Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications","volume":"14","author":"Wu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mvr.2026.104955_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mvr.2026.104955_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mvr.2026.104955_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1039378","article-title":"Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."},{"issue":"33","key":"10.1016\/j.mvr.2026.104955_bb0625","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","article-title":"The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer","volume":"27","author":"Yang","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mvr.2026.104955_bb0630","article-title":"Vascular normalization: a new window opened for cancer therapies","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mvr.2026.104955_bb0635","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.actbio.2023.10.018","article-title":"Iridium nanozyme-mediated photoacoustic imaging-guided NIR-II photothermal therapy and tumor microenvironment regulation for targeted eradication of cancer stem cells","volume":"172","author":"Yao","year":"2023","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.mvr.2026.104955_bb0640","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of immunotherapy combination strategies in cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0645","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000564","article-title":"Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with pretreated biliary tract cancer","volume":"8","author":"Yoo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0650","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41592-020-01020-3","article-title":"Mapping the functional landscape of T cell receptor repertoires by single-T cell transcriptomics","volume":"18","author":"Zhang","year":"2021","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.mvr.2026.104955_bb0655","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: from molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.mvr.2026.104955_bb0660","article-title":"Spatiotemporal imaging of immune dynamics: rethinking drug efficacy evaluation in cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mvr.2026.104955_bb0665","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Microvascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286226000555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026286226000555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:40:29Z","timestamp":1783960829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026286226000555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":133,"alternative-id":["S0026286226000555"],"URL":"https:\/\/doi.org\/10.1016\/j.mvr.2026.104955","relation":{},"ISSN":["0026-2862"],"issn-type":[{"value":"0026-2862","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microvascular and stromal normalization combined with nano-immunotherapy: A synergistic strategy to overcome drug delivery barriers in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Microvascular Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mvr.2026.104955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104955"}}